XML 37 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2022
Feb. 24, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2022    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Trading Symbol RPTX    
Entity Registrant Name Repare Therapeutics Inc.    
Entity Central Index Key 0001808158    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 454,878,023
Entity Common Stock, Shares Outstanding   42,077,896  
Title of 12(b) Security Common Shares, no par value    
Security Exchange Name NASDAQ    
Entity File Number 001-39335    
Entity Incorporation, State or Country Code A8    
Entity Tax Identification Number 00-0000000    
Entity Address, Address Line One 7210 Frederick-Banting    
Entity Address, Address Line Two Suite 100    
Entity Address, City or Town St-Laurent    
Entity Address, State or Province QC    
Entity Address, Country CA    
Entity Address, Postal Zip Code H4S 2A1    
City Area Code 857    
Local Phone Number 412-7018    
Document Annual Report true    
Document Transition Report false    
ICFR Auditor Attestation Flag false    
Documents Incorporated by Reference

Portions of the definitive proxy statement for the registrant’s 2023 annual meeting of shareholders, which is to be filed within 120 days after the end of the registrant’s fiscal year ended December 31, 2022, are incorporated by reference into Part III of this Form 10-K, to the extent described in Part III.

   
Auditor Firm ID 1263    
Auditor Name Ernst & Young LLP    
Auditor Location Montréal, Canada